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Targeted delivery remains the major challenge for the 
application of small interfering RNA (siRNA). We have 
developed a lipid/calcium/phosphate (LCP) nanoparticle 
(NP) to improve siRNA delivery efficiency. The LCP NP 
was prepared by using microemulsion technology to 
form calcium/phosphate (CaP) core and further coated 
with cationic lipids. The final NP was grafted with poly-
ethylene glycol (PEG) and anisamide (AA) ligand on the 
surface to target sigma receptor-expressing B16F10 
melanoma cells. The LCP NP exhibited a 40 nm particle 
size, a +25 mV zeta-potential, and 91% siRNA encapsu-
lation efficiency. After a single intravenous (i.v.) injection 
of antiluciferase siRNA (0.12 mg siRNA/kg) formulated in 
targeted LCP NP, luciferase activity in metastatic B16F10 
tumor-loaded lungs decreased by 78% in C57BL/6 mice. 
In a therapeutic experiment, siRNA against MDM2, 
c-myc, and VEGF coformulated in the targeted LCP 
NP resulted in simultaneous silencing of the respective 
oncogenes in metastatic nodules. Treatment with siRNA 
in the targeted NP significantly reduced lung metasta-
ses (~70–80%) at a relatively low dose (0.36 mg/kg), 
whereas control group showed little therapeutic effect. 
Moreover, this targeted LCP NP significantly prolonged 
the mean survival time of the animals by 27.8% com-
pared to control group without showing any toxicity at 
the therapeutic dose.
Received 2 September 2011; accepted 14 November 2011;  
published online 20 December 2011. doi:10.1038/mt.2011.270
IntroductIon
Metastasis is a complex process requiring tumor cell detachment 
from the primary tumor and migration to secondary site.1 Because 
of this dangerous aggressiveness, metastatic disease is a leading 
cause of cancer mortality. The lung, in particular, is a common 
site of metastasis due to its anatomic and functional structure. 
Moreover, the lung is highly vascular and rich in oxygen, provid-
ing not only pathways for metastatic seeding, but also a nutrient-
rich environment for neoplastic growth.2 Tumor lung metastases 
are found in 20–54% of deceased cancer patients.3 Surgical resec-
tion is a widely accepted procedure for treating lung metastases. 
Unfortunately, due to local and distant recurrences, the reported 
5-year survival rates for patients with metastatic disease are only 
30–40% even after complete resection. Chemotherapy, in particu-
lar, is helpful in preventing metastasis. However, chemotherapy is 
often associated with serious side effects that significantly lower 
patients’ quality of life. Thus, novel systemic treatments of tumor 
metastasis are urgently needed.4,5
RNA interference technology has stood out as one of the 
most attractive new antitumor therapeutics because of its revo-
lutionary potency and selectivity for targeted gene silencing.6 
However, the practical applications of small interfering RNA 
(siRNA) are limited for its inherent instability against nucleases 
and poor bioavailability.7 Therefore, efficient and biocompatible 
methods of in vivo siRNA delivery are needed to realize its full 
therapeutic potential. Recently, we have developed a novel siRNA 
delivery vehicle, the “lipid/calcium/phosphate” (LCP) nanopar-
ticle (NP), by replacing the protamine/DNA core in our previous 
well-established LPD (liposome/polycation/DNA) formulation 
with a pH-sensitive calcium phosphate (CaP) core. Although 
the LPD formulation has shown success in delivering siRNA for 
metastatic lung tumor treatment, improvements were needed to 
address the low siRNA release efficiency and moderate toxicity.8–12 
CaP is considered as an ideal biomaterial for various biomedi-
cal applications, because it is biocompatible, biodegradable, and 
native to the body as the principle mineral component of teeth 
and bones.13,14 Calcium ions are also known to form complexes 
with the nucleic acid backbone and thus may stabilize certain 
DNA structures.15 Moreover, CaP can rapidly dissolve at the 
acidic endosome pH, releasing its cargo into the cytoplasm.12 We 
have earlier shown that compared to the LPD formulation, our 
targeted LCP NP releases more cargo to the cytoplasm, leading to 
a significant (~40-fold in vitro and ~4-fold in vivo) improvement 
in siRNA delivery.
In the present study, we aim to investigate the feasibility of 
the LCP NP as a siRNA delivery vector for the treatment of meta-
static tumors. Based on previous findings, we hypothesized that 
our LCP NP could prolong the circulation time and elevate endo-
some release efficiency of siRNA, lowering the required siRNA 
dose and the in vivo toxicity of the delivery system. To this end, an 
experimental lung metastasis model was established by the intra-
venous (i.v.) injection of murine melanoma cells (B16F10 cells 
stably transduced with the firefly luciferase gene) into C57BL/6 
mice. In vivo gene silencing efficiency was assayed using antilu-
ciferase siRNA formulated in targeted or nontargeted LCP NP. 
In order to evaluate the therapeutic efficacy of LCP NP, we chose 
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a combination treatment of three different siRNA sequences 
(MDM2/c-myc/VEGF = 1:1:1, weight ratio), which has been 
shown to have a synergistic antitumor effect on B16F10 tumor 
metastasis.11,16
results and dIscussIon
characterization of lcP nP
CaP NPs represent a unique class of nonviral vectors, which has 
the potential to be an efficient, alternative siRNA delivery system. 
Although many studies have been performed to prepare nanosized 
CaP NPs to improve transfection reproducibility and efficiency, 
no method has produced colloidally stable particles. Typically, 
significant agglomeration is observed, which hampers the in vivo 
application of the CaP NP.17–19 In the present study, we have used 
a newly developed CaP NP formulation, named LCP, to deliver 
therapeutic siRNAs in a mouse lung metastasis model of mela-
noma. The salient features of LCP include an asymmetrical lipid 
bilayer coating the CaP core that encapsulates siRNA. To enhance 
tumor uptake, LCP was coated with polyethylene glycol (PEG) 
(2 kDa) and anisamide (AA) targeting ligand for the sigma recep-
tor overexpressing melanoma cells. The characteristics of the LCP 
NP are summarized in Table 1. The final LCP NP was ~40 nm 
in size, with a zeta-potential around 25 mV. The particle sizes of 
nontargeted and targeted NP formulations were similar to each 
other. The zeta-potential of the targeted NP was slightly higher 
than that of the nontargeted NP due to the positively charged AA 
ligand. Additionally, neither the nontargeted nor the targeted LCP 
NP formed aggregates in 50% serum (data not shown). The siRNA 
trapping efficiency of the LCP NP was determined to be ~91% 
using Texas red-labeled siRNA.
In vivo luciferase gene silencing
To evaluate the in vivo delivery efficiency of targeted LCP NP, 
we encapsulated luciferase siRNA and injected the targeted 
LCP NP into B16F10 tumor-bearing mice via the tail vein. The 
results indicated that targeted LCP NP could significantly silence 
luciferase expression (78%) when compared the untreated group 
(Figure 1a). Quantitative PCR also revealed that the luciferase 
mRNA level in the targeted LCP NP group was downregulated by 
80% compared to that of control groups (Figure 1b). Furthermore, 
a dose–response assay indicated that the ED50 of the targeted LCP 
NP formulation was 60 μg/kg. The optimal dose for the maxi-
mum gene silencing effect was 120 μg/kg; further dose increases 
did not result in a higher luciferase silencing activity (Figure 1c). 
We have shown that our previous LPD formulation is strikingly 
successful for delivering siRNA after i.v. injection in the B16F10 
metastasis model (ED50 = 75 μg/kg).
11 However, the LPD particle 
demonstrates variable release of siRNA into the cytoplasm among 
different cells. Thus, we replaced the protamine/DNA core of LPD 
with a pH sensitive CaP core, which could dissolve in the low pH 
microenvironment of the endosome, increase the osmotic pres-
sure, and cause endosome swelling and bursting for a more consis-
tent release of entrapped siRNA into the cytoplasm.12 Consistent 
with this finding, the current study has shown that replacing the 
protamine/DNA core with CaP decreased the ED50 of the targeted 
NP formulation. Therefore, the enhanced activity of our present 
formulation is probably due to improved endosome release effi-
ciency. Moreover, without the targeted ligand, the LCP NP only 
showed slight luciferase silencing, demonstrating that the targeted 
LCP NP can specifically bind to metastatic tumor cells and medi-
ate ligand-induced endocytosis.
In vivo antitumor/antimetastasis study
Based on the in vivo luciferase gene silencing study, we next evalu-
ated the potential of our novel LCP NP as a siRNA delivery vehicle 
for the treatment of tumor metastasis in the lung by encapsulat-
ing combined siRNA sequences in the LCP NP (MDM2/c-myc/
VEGF = 1:1:1, weight ratio). In most cancers, the inhibition of a 
single gene is insufficient to suppress tumor growth. The simulta-












































































































































































Figure 1 In vivo luciferase gene silencing effect of lucifersase small interfering rna (sirna) in lipid/calcium/phosphate (lcP) nanoparticle 
(nP). (a) Luciferase activity in each group. The luciferase activity was compared to the untreated control and expressed as % luciferase activity. 
(b) mRNA level of luciferase in each group was determined by quantitative reverse trancriptase (qRT)-PCR. (c) Dose–response curve of luciferase 
siRNA formulated in targeted LCP NP. Data = mean ± SD (n = 5). *P < 0.05.
table 1 characterization of lcP nP formulations
 nontargeted lcP nP targeted lcP nP
Particle size (nm) 40 ± 3 38 ± 5
Zeta-potential (mv) 20 ± 2 25 ± 3
Abbreviations: LCP, lipid/calcium/phosphate; NP, nanoparticle.
The particle size and zeta-potential of nontargeted and targeted LCP NP were 
measured using a Zetasizer. Data are representative data from repeated measures 
of 3–4 samples.
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to result in an enhanced therapeutic effect.20,21 MDM2 is an inte-
gral part of one such destructive pathway, acting as a crucial nega-
tive regulator of p53 and the major suppressor of p53 function 
in tumors with aberrant MDM2 expression.22 In addition, the 
activated c-myc transcription factor controls a broad spectrum 
of functions including proliferation and cell cycle, differentia-
tion, sensitization to apoptotic stimuli, and genetic instability.23 
Tumors can also secrete VEGF growth factor to mediate tumor 
angiogenesis and metastasis.24 In this study, we formulated three 
combination siRNAs (0.36 mg/kg, MDM2/c-myc/VEGF = 1:1:1, 
weight ratio) in targeted LCP NP and treated tumor-bearing mice 
on day 6, 8, 10, and 12 with i.v. injections to evaluate the therapeu-
tic outcomes. As shown in Figure 2a, metastatic nodules were sig-
nificantly reduced in lungs from mice treated with four systemic 
injections of siRNA formulated in the targeted LCP NP, whereas 
control siRNA formulated in targeted LCP NP had little therapeu-
tic effect. Hematoxylin and eosin (H&E) staining also showed that 
lungs treated with combinations of siRNA in the targeted LCP NP 
contained only a few small nodules; most of the lung was free of 
tumor. In contrast, metastasis nodules occupied most of the lung 
tissue from control groups (Figure 2b).
To further quantify the B16F10 nodules in the lung, one lobe of 
the excised lung was homogenized and assayed for luciferase activ-
ity. As shown in Figure 2c, therapeutic siRNA in the targeted NP 
significantly reduced the tumor load to 20–30% as compared to the 
tumor load of the untreated control (P < 0.01). The therapeutic out-
come was also analyzed in terms of animal survival (Figure 2d). 
On day 25, the survival rates for untreated controls, therapeutic 
siRNA in the targeted LCP NP, and control siRNA in the targeted 
LCP NP were 0, 0, 40, and 100%, respectively (Figure 2d), and the 
mean survival times were 22.3, 23.2, 25.1, and 28.5 days, respec-
tively. Therapeutic siRNA in targeted and nontargeted LCP NP 
significantly improved animal survival compared to an untreated 
group (P < 0.001). Control siRNA in the targeted NP did not 
improve animal survival compared to untreated group (P > 0.05). 
Although siRNA in nontargeted did not reduce the tumor burden, 
animal longevity was improved significantly compared to control 
groups. The results suggested that multiple dosing might compen-
sate for the relatively poor uptake efficiency of the nontargeted NP. 
Even though the results were statistically significant, nontargeted 
NP showed only moderate increases in animal lifespan. Targeted 
LCP NP, on the other hand, demonstrated much higher uptake and 
release efficiency for lung metastasis tumor cells and not only sig-
nificantly reduced the tumor load in the lung (Figure 2a–c), but 
also prolonged survival by ~27.8% (Figure 2d).
In vivo antitumor/antimetastasis mechanism
To elucidate the mechanism underlining the antitumor/antime-
tastasis effect of the targeted LCP NP, gene silencing activity was 
measured using immunohistochemistry (Figure 3a), western blot-
ting (Figure 3b) as well as enzyme-linked immunosorbent assay 
analysis (Figure 3c), respectively. As shown in Figure 3b,c, after two 
i.v. injections on days 10 and 12 (dose = 0.36 mg/kg) of therapeutic 
siRNA formulated in the targeted LCP NP, gene expression levels of 
MDM2, c-myc, and VEGF were silenced in B16F10 lung metasta-
ses, whereas other control treatments, including siRNA in nontar-
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Figure 2 antimetastasis efficacy of therapeutic small interfering 
rna (sirna) in lipid/calcium/phosphate (lcP) nanoparticle (nP). 
(a) Photographs of lungs excised from the tumor-bearing mice on day 
19 after four treatments. n = 5–6. (b) Quantification of lung metastasis 
by measuring luciferase activity on day 19 after four injections. n = 9–10. 
(c) Images of hematoxylin and eosin (H&E) H&E staining of the lung tis-
sue sections. Original magnification, ×40. (d) Survival analysis of B16F10 
lung metastases–bearing mice after four injections. n = 10. *P < 0.05; 
**P < 0.01, ***P < 0.001.
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effect. The data from the western blotting analysis was consistent 
with the data obtained from the immunohistochemical analysis.
The harvested B16F10 tumors were also stained for apoptotic 
markers. Figure 4 indicated that ~11% of B16F10 tumor cells treated 
with combination siRNA formulated in targeted NP underwent 
apoptosis detected by TdT-mediated dUTP Nick-End Labeling 
(TUNEL) staining. This value was higher than that of tumors in 
control groups. Moreover, we did not detect any apoptosis in the 
normal lung tissue area from the targeted LCP NP-treated group. 
Therefore, our in vivo results show that the antitumor/antimetas-
tasis activity was highly dependent on the LCP NP formulation 
and the sequence of the encapsulated siRNA.
no immune response or major organ damage was 
observed after treatment with sirna formulated 
in targeted lcP nP
A drug agent should not only be therapeutically effective, but 
must also exhibit acceptably low levels of toxicity. Recent in vitro 
reports have shown that siRNA sequences and their method of 
delivery might induce an interferon response.25–27 Additionally, 
in vivo delivery of siRNA by lipids has resulted in potent inter-
feron responses.28,29 Here, a single tail-vein injection of the siRNA 
formulated in the targeted NP was performed to measure blood 
markers indicative of an immune response. At the therapeutic 
dose (0.36 mg/kg), the targeted NP did not induce significant 
production of any analyzed cytokines, including interleukin 
(IL)-6, IL-12, tumor necrosis factor, and interferon-γ at 2 or 6 
hours after injection (Figure 5a). Furthermore, when the dose 
was increased twofold, inflammatory toxicity was not signifi-
cantly enhanced (Figure 5a). Levels of secreted liver enzymes 
(aspartate aminotransferase and alanine aminotransferase), and 
blood urea nitrogen were all unchanged after a long-term treat-
ment with therapeutic siRNA in targeted LCP NP, indicating a 
lack of damage to the liver or kidneys (Table 2). We also did a 
pathologic examination of the major organs (liver, kidney, spleen, 
heart) from the mice that received long-term treatments by H&E 
staining (Figure 5b). No organ damage was observed samples 
from mice treated with the formulated LCP NP. We have earlier 
shown that at neutral pH 7.0, both CaP and LCP NP remained 
unchanged.12 Therefore, the LCP NP does not affect the serum lev-
els of calcium and the cardiovascular physiology. Additionally, the 
body weight of experimental mice did not significantly decrease 
during treatment at the therapeutic dose (data no shown). Taken 
together, these results show the safety and low immunogenicity of 
LCP formulations and the attractiveness of this methodology for 
systemic, targeted delivery of nucleic acids.
Figure 3 oncogenes silencing in the lung metastasis. (a) Immunostaining of MDM2 and c-myc in the B16F10 lung metastatic nodules after two 
injections of small interfering RNA (siRNA) in different formulations. Original magnification ×100. (b) The protein levels MDM2 and c-myc in 
the B16F10 tumor-loaded lung were determined by using western blot analysis. (c) Intratumoral expression of VEGF after treatment with siRNA in 
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In summary, systemic delivery of siRNA by targeted LCP NP 
can provide safe, sequence-specific inhibition of tumor growth 
in a metastasis tumor model. The targeted siRNA LCP NP for-
mulations are efficacious at low siRNA doses (0.12 mg/kg) and do 
not require chemical modification of the siRNA for stabilization. 
Furthermore, this delivery system can be easily tuned to target 
different cell-surface receptors in tumors and other tissue and 
does not elicit a detectable immune response or any changes in 
mouse physiology. We believe that this treatment has the poten-
tial to be developed into a useful method for inhibiting metastatic 
tumor growth. Future experiments using a tumor-specific target-
ing ligand and employing formulation combinations with small- 
molecule drugs are likely to further enhance the antitumoral 
potency of this system. We therefore conclude that siRNA formu-
lated in targeted LCP NP has the potential to become a useful tool 
in cancer therapy.
MaterIals and Methods
Materials. 1,2-Dioleoyl-3-trimethylammonium-propane chloride salt 
(DOTAP), dioleoylphosphatydic acid (DOPA), and 1,2-distearoryl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol-2000) 
table 2 serum levels of alt, ast and Bun after long-term treatment 
with therapeutic sirna in the targeted lcP nP
 alt (u/l) ast (u/l) Bun (mg/dl)
Untreated group 55.5 ± 9.12 140.5 ± 10.61 16 ± 2.83
Therapeutic siRNA in targeted  
LCP NP-treated group
58.33 ±17.5 149.33 ± 24.91 20 ± 5.29
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
LCP, lipid/calcium/phosphate; NP, nanoparticle; siRNA, small interfering RNA.
Measurements were carried out with the aim of evaluating the potential long-
term toxicity of therapeutic siRNA in the targeted LCP NP. Data = mean ± SD 
(n = 5).
Figure 4 tdt-mediated dutP nick-end labeling (tunel) assay. Forty-eight hours after two injections of small interfering RNA (siRNA) in 
different formulations, tumor-loaded lung were collected, sectioned and stained using a TUNEL kit. (a) The apoptosis was apparent in therapeutic 
siRNA in targeted lipid/calcium/phosphate (LCP) nanoparticle (NP)-treated tumors. (b) No apoptosis was observed in the normal lung area from 





















































































Figure 5 toxicity analysis. (a) Serum cytokine assay. Serum was collected and assessed for interleukin (IL)-12, IL-6, interferon (IFN)-γ and tumor 
necrosis factor (TNF) at indicated time following intravenous injections of the therapeutic small interfering RNA (siRNA) in targeted nanoparticle 
at different doses. Data = mean ± SD (n = 5). (b) Hematoxylin and eosin (H&E) staining of the major organs (liver, kidney, spleen, heart) from the 
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ammonium salt (DSPE-PEG2000) were purchased from Avanti Polar 
Lipids (Alabaster, AL). DSPE-PEG-AA (AA) was synthesized in our lab 
as described previously.30 Other chemicals were obtained from Sigma-
Aldrich (St Louis, MO) without further purification.
Mouse monoclonal primary antibodies against mouse MDM2, c-myc, 
GAPDH, and secondary antibodies conjugated with horseradish 
peroxidase (goat anti-mouse IgG horseradish peroxidase) were purchased 
from Santa Cruz Biotechnologies (Santa Cruz, CA).
Cell line. Murine melanoma cell line B16F10 cells, sigma receptor-pos-
itive, were obtained from American Type Culture Collection and stably 
transduced with the GL3 firefly luciferase gene using a retroviral vector in 
Dr Pilar Blancafort’s Laboratory at the University of North Carolina at 
Chapel Hill. The cells were maintained in Dulbecco’s modified Eagle’s 
medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine 
serum (Invitrogen).
Experimental animals. Female C57BL/6 mice of ages 4–6 weeks were 
purchased from the National Cancer Institute (Bethesda, MD). All experi-
ments performed on the animals were in accordance with and approved by 
the Institutional Animal Care and Use Committee at University of North 
Carolina. A murine model of lung metastasis was established by intrave-
nously injecting 2 × 105 B16F10 cells into the C57BL/6 mice.
siRNA. Luciferase siRNA (target sequence: 5′-CUU ACG CUG AGU ACU 
UCG A-3′), MDM2 siRNA (target sequence: 5′-GCU UCG GAA CAA 
GAG ACU C-3′), c-myc siRNA (target sequence: 5′-GAA CAU CAU CAU 
CCA GGA C-3′), VEGF siRNA (target sequence: 5′-CGA UGA AGC CCU 
GGA GUG C-3′), and control siRNA (target sequence: 5′-AAU UCU CCG 
AAC GUG UCA CGU-3′) were purchased from Dharmacon (Lafayette, 
CO) in unprotected, desalted, annealed form. Those sequences were 
adopted from published studies.11,16
Preparation of siRNA containing LCP NP. LCP NP was prepared as 
described previously with slight modifications.12 Briefly, 600 μl of 2.5 mol/l 
CaCl2 with 48 μg of siRNA was dispersed in a 20 ml oil phase [cyclohexane/
lgepal CO-520 (71/29, vol/vol)] to form a well-dispersed water-in-oil 
reverse microemulsion. The phosphate microemulsion was prepared by 
dispersing 600 μl of 12.5 mmol/l Na2HPO4 (pH = 9.0) in a separate 20 ml 
oil phase. Two-hundred μl (20 mmol/l) DOPA in chloroform was added 
to the phosphate solution. After mixing the above two microemulsions for 
20 minutes, 40 ml of absolute ethanol was added to the combined solu-
tion and the mixture was centrifuged at 12,000g for at least 15 minutes to 
remove the cyclohexane and surfactant. After 2–3 ethanol washes, the CaP 
core pellets were dissolved in 4 ml of chloroform and were stored in glass 
vial. To prepare the final LCP NP, 500 μl of CaP core was mixed with 75 μl 
of 10 mmol/l DOTAP, 10 mmol/l cholesterol, 3 mmol/l DSPE-PEG2000 and 
3 mol/l DSPE-PEG-AA. After evaporating the chloroform, the residual 
lipid was hydrated in 200 μl of 5% glucose to form the LCP NP. The zeta-
potential and particle size of the final LCP NP was detected in 1 mmol/l 
KCl by a Malvern ZetaSizer Nano series (Westborough, MA). The trapping 
efficiency of siRNA in LCP NP was determined as described previously 
using Texas Red-labeled siRNA.
In vivo luciferase gene silencing study. Tumor-bearing mice were given 
i.v. injection of antiluciferase siRNA at the dose of 0.12 mg/kg formulated 
in different LCP formulations. Control siRNA formulated in targeted LCP 
NP was also prepared to verify whether the silencing effect was sequence-
dependent. For a dose–response study, tumor-bearing mice were i.v. 
injected with siRNA in targeted LCP NP at dose of 0.03, 0.06, 0.12, 0.24, 
or 0.48 mg/kg, respectively. After 24 hours, mice were sacrificed and their 
lungs were collected. The tumor-loaded lung was homogenized in 1 ml 
lysis buffer (0.05% Triton X-100 and 2 mmol/l EDTA in 0.1 mol/l–HCl) fol-
lowed by centrifugation at 5,000g for 5 minutes. Ten μl of supernatant was 
mixed with 90 μl luciferase substrate (Luciferase Assay System; Promega, 
Madison, WI), and the luciferase activity was measured by a plate reader. 
The protein concentrations of the samples were determined by using BCA 
protein assay kit (Pierce, Rockville, MD). Luciferase activity of a sample 
was normalized with the protein content and expressed as percent lumi-
nescence intensity compared to the untreated control.
To determine the intratumoral level of luciferase mRNA, total RNA was 
extracted from the tumor-loaded lung using an RNeasy Mini Kit (Qiagen, 
Valencia, CA), and individual cDNAs were synthesized with a SuperScript 
II reverse transcriptase assay (Invitrogen). Real-time quantitative PCR was 
performed with a SYBR GreenER quantitative PCR SuperMix Universal kit 
(Invitrogen). Reactions were run with a standard cycling program; 50 °C for 
2 minutes, 95 °C for 10 minutes, 40 cycles of 95 °C for 15 seconds, and 60 °C 
for 1 minutes, on an AB7500 real-time PCR system (Applied Biosystems, 
Foster City, CA). The PCR primers to detect luciferase (forward; 5′-GAA 
GAG ATA CGC CCT GGT TC-3′, reverse; 5′-GGC TGC GAA ATG TTC 
ATA CT-3′) and GAPDH (forward; 5′-ATG GGG AAG GTG AAG GTC 
G-3′, reverse; 5′-TAA AAG CAG CCC TGG TGA CC-3′) were synthesized 
and purified by IDT (Coralville, IA).
In vivo oncogenes silencing study. Tumor-bearing mice were given two i.v. 
injections of control siRNA formulated in LCP NP (0.36 mg/kg), therapeutic 
siRNA (MDM2/c-myc/VEGF = 1:1:1, weight ratio, 0.36 mg/kg) formulated 
in nontargeted LCP NP or therapeutic siRNA formulated in targeted LCP 
NP on days 10 and 12 after B16F10 cells inoculation. One day after the sec-
ond injection, the mice were sacrificed and the tumor-loaded lungs were 
collected and embedded in paraffin. Immunohistological analysis of MDM2 
and c-myc gene expression for extracted tissues was performed using MDM2 
and c-myc monoclonal antibodies. Cell nuclei were counterstained with 
hematoxylin, and all the specimens were examined with a Nikon light micro-
scope (Nikon, Tokyo, Japan). For western blotting, tumor-loaded lungs were 
homogenized in RIPA lysis buffer (50 mmol/l Tris, 150 mmol/l NaCl, 1% 
Triton, 0.5% deoxycholate, 2 mmol/l EDTA) supplemented with a 100× pro-
tease inhibitor cocktail (Sigma-Aldrich). Twenty μg of total protein extracted 
from the tumor-loaded lung was resolved on a sodium dodecyl sulfate poly-
acrylamide gel electrophoresis gel and then transferred to a polyvinylidene 
fluoride membrane. The membranes were blocked with 5% nonfat milk in 
Tris-buffered saline for 1 hour and were then incubated overnight with pri-
mary antibody at 4 °C. After five Tris-buffered saline washes (1% Tween-20 
in Tris-buffered saline), the membranes were incubated with an horseradish 
peroxidase-conjugated secondary antibody for 1 hour. The peroxidase activ-
ity associated with the protein bands was detected with enhanced chemilu-
minescence using ECL plus (GE Health Care, Buckinghamshire, UK). To 
quantify the expression level of VEGF, the tumor-loaded lung was homog-
enized in phosphate-buffered saline and centrifuged at 5,000g for 5 minutes. 
Cell supernatant was collected and the concentration of VEGF was deter-
mined by using Quantikine mouse VEGF enzyme-linked immunosorbent 
assay kit (R&D Systems, Minneapolis, MN) according to the manufacturer’s 
instructions. The sample concentration was calculated from the standard 
curve. All enzyme-linked immunosorbent assay data was corrected for total 
protein. Each experiment was performed in triplicate.
TUNEL assay. To detect apoptotic cells in tumor tissues, a TUNEL assay, using 
a DeadEndTM Fluorometric TUNEL System (Promega), was performed, 
following the manufacturer’s protocol. Cell nuclei that were fluorescently 
stained dark green were defined as TUNEL-positive nuclei. TUNEL-positive 
nuclei were monitored by using a fluorescence microscope (Nikon, Tokyo, 
Japan). To quantify TUNEL-positive cells, green-fluorescence-positive cells 
were counted in 10 random 0.011-mm2 fields at ×200 magnification.
In vivo metastasis inhibition study and survival analysis. Tumor-bearing 
mice were given i.v. injections of control siRNA formulated in targeted 
LCP NP (0.36 mg/kg), therapeutic siRNA (MDM2/c-myc/VEFG = 1:1:1, 
weight ratio, 0.36 mg/kg) formulated in nontargeted LCP NP or therapeutic 
siRNA formulated in targeted LCP NP on days 6, 8, 10, and 12. On day 19, 
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the mice were sacrificed and the tumor-loaded lungs were collected. One 
lobe of each lung was analyzed for luciferase activity in order to quantify 
the lung metastasis nodules. The lobe was homogenized in 1 ml of lysis 
buffer (0.05% Triton X-100 and 2 mmol/l EDTA in 0.1 mol/l Tris–HCl) fol-
lowed by centrifugation at 5,000g for 5 minutes. Ten μl of the supernatant 
was mixed with 90 μl of luciferase substrate, and the luciferase activity was 
measured using a plate reader. The rest of the lung was fixed in 4% neutral 
paraformaldehyde solution overnight and embedded in paraffin followed 
by H&E staining. For the survival analysis study, tumor-bearing mice were 
treated on days 6, 8, 10, and 12. The mice were sacrificed if they exhibited 
a weight loss >10% or showed ruffled fur.
Toxicity, immune response, and pathology studies. The C57BL/6 mice 
were i.v. injected with siRNA (MDM2/c-myc/VEGF = 1:1:1) formulated 
in the targeted LCP NP at a dose of 0.36 mg/kg or 0.72 mg/kg. Two and 
six hours after the injection, blood samples were collected and allowed to 
clot for 2 hours at room temperature. Serum was obtained by centrifug-
ing for 20 minutes at 2,000g and the serum cytokine level was determined 
using enzyme-linked immunosorbent assay kits for IL-6, IL-12, TNF-α 
and interferon-γ (BD Biosciences, San Diego, CA). For liver and renal 
function experiments, mice were i.v. injected with siRNA (MDM2/c-myc/
VEGF = 1:1:1, 0.36 mg/kg) formulated in the targeted LCP NP every other 
day for four times. The levels of aspartate aminotransferase, alanine amin-
otransferase, and blood urea nitrogen in serum were measured 1 day after 
the last injection. Major organs of the C57BL/6 mice were collected after 
treatment, formalin fixed, and processed for routine H&E staining using 
standard methods. Images were collected using a Nikon light microscope 
(Nikon).
Statistical analysis. Data was presented as mean values ± SD. The sta-
tistical significance was determined using one-way ANOVA. The animal 
survival data was analyzed using Kaplan–Meier survival analysis. P values 
<0.05 were considered significant.
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